ArticleMolecular nutrition & food research2025
Effectiveness of Ethanol Extract of Rosa rugosa Thunb. on Ear Edema.
Article in Molecular nutrition & food research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Effectiveness of Ethanol Extract of Rosa rugosa Thunb. on Ear Edema.Molecular nutrition & food research · 2025Article
- Recent Advances in Bioactive Compounds, Health Functions, and Utilization of Rose (Molecules (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
This study investigated the anti-inflammatory and skin barrier-restoring effects of a 50% ethanol extract of Rosa rugosa Thunb. (RT50) using both in vitro and in vivo models, including HaCaT keratinocytes and a 1-Chloro-2,4-dinitrobenzene (DNCB)-induced ear edema mouse model. The aim was to evaluate the potential efficacy of RT50 in treating hypersensitivity-related skin conditions, such as atopic and contact dermatitis, and to explore natural therapeutic alternatives with fewer side effects for managing inflammatory skin diseases. Cytotoxicity testing identified non-toxic concentrations of 10, 30, and 60 µg/mL for further analysis. RT50 significantly reduced tumor necrosis factor-α/interferon-γ-induced pro-inflammatory cytokines and chemokines in HaCaT cells, demonstrating its anti-inflammatory properties. In vivo, treatment with RT50 significantly reduced DNCB-induced ear edema, as confirmed by histological analysis. Epidermal and dermal thickness and mast cell infiltration were reduced in a concentration-dependent manner. Serum analysis showed that RT50 decreased elevated levels of Immunoglobulin E/Immunoglobulin G caused by DNCB exposure. The gene expression results further showed that RT50 suppressed DNCB-induced pro-inflammatory cytokines and chemokines in ear tissues. Additionally, RT50 restored skin barrier integrity, which was disrupted by DNCB. Key skin barrier proteins, including filaggrin, involucrin, and loricrin, showed increased expression after RT50 treatment. Factors associated with tight junctions were also positively affected, suggesting that RT50 may play a key role in repairing skin barrier function. These findings highlight RT50 as a promising therapeutic candidate for addressing inflammatory skin conditions by both reducing inflammation and restoring skin barrier integrity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.